Piriformis Syndrome; Extracorporeal Shock Wave Therapy and Dry Needling

Comparison of the Efficacy of ESWT and Dry Needling Treatments in the Management of Piriformis Syndrome; A Randomized Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06530862

Enrollment

Registered

2024-07-31

Start date

2024-02-03

Completion date

2024-08-23

Last updated

2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Shock Wave Therapy, Piriformis Syndrome

Keywords

ESWT, Dry Needling, Piriformis Syndrome

Brief summary

This study is being conducted on patients with piriformis syndrome. Patients are divided into two groups by list randomization method: Extracorporeal shock wave therapy (ESWT) group and Dry neddling (DN) group. Both groups of patients agreed to perform basic stretching exercises. The ESWT group received 3 sessions of radial ESWT, 1 session per week. The DN group received 3 sessions of ultrasound-guided needling, 1 session per week. Clinical evaluations of the participants were performed at the beginning of treatment, 1 month, and 3 months after treatment.

Interventions

OTHERESWT+stretching exercises

Participants in this group will receive ESWT treatment

OTHERDry needling+stretching exercises

Participants in this group will receive Dry needling treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Participants will be randomly divided into 2 groups and will be treated with ESWT or Dry needling

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>18 years * Complaint for more than 3 months

Exclusion criteria

* disc pathologies according to radiological imaging * hip joint and soft tissue pathologies * recent history of trauma, history of surgery in the lumbar and hip region * history of rheumatologic disease * history of polyneuropathy * history of sciatic nerve injury * history of malignancy * opioid analgesia or corticosteroid intervention for pain in the last month * patients receive another treatment during the study * Having a contraindication for DN treatment or ESWT treatment

Design outcomes

Primary

Measure	Time frame	Description
Visual analog scale (VAS) score	7 months	Pain was evaluated with a Visual analog scale (VAS) score
Lower extremity functiunal scale (LEFS)	7 months	Pain was evaluated with a Lower extremity functiunal scale (LEFS (minimum=0, maximum=80)) The higher the score, the better the result
Oswestry disability index (ODI)	7 months	Pain was evaluated with a Oswestry disability index (ODI (minimum=0, maximum=60))The lower the score the better the result

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026